KYV-101 clinical trials

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

This study is testing a new cell therapy called KYV-101 for people with a type of muscle weakness called myasthenia gravis. It aims to see if this therapy, which targets specific immune cells, can help reduce symptoms and improve daily life for patients.